HitGen
Business Services · China · 201-500 Employees
View Company Info for Free
Overview
Headquarters
88 S Keyuan Rd, Chengdu, Jiangxi, ChinaPhone Number
+86 2885197385Website
www.hitgen.comRevenue
$11.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About HitGen
HitGen Inc. is a rapidly developing biotech company headquartered in Chengdu, China, specializing in drug discovery and development of novel medicines and agrochemicals. The company utilizes advanced technology platforms, including DNA-encoded library technology and fragment-based drug discovery, to optimize small molecules and nucleic acid-based drugs. HitGen collaborates with numerous biopharmaceutical research organizations globally, offering a comprehensive range of services from early discovery to clinical trial stages. Their innovative DEL+AI+Automated DMTA platform aims to accelerate the optimization of preclinical candidate compounds.Explore more
HitGen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HitGen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if HitGen had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at HitGen
Check out if HitGen is spiking on competitors!
Product Launch: Get notified when HitGen launches new products
Funding: Get notified immidiatlly once HitGen has new funding data
Check if HitGen has recently received funding, and reach out quickly before it becomes old news!
HitGen, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on HitGen recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined HitGen as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
HitGen is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
HitGen is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about HitGen.
HitGen Tech Stack
A closer look at the technologies used by HitGen
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
HitGen News & Media
HitGen Submits Commitment Letter to Science Based Targets initiative (SBTi)
CHENGDU, China, Dec. 15, 2025 /PRNewswire/ -- HitGen Inc. (hereinafter referred to as "HitGen", SSE: 688222.SH), announced it has officially submitted its commitment letter to the Science Based Targets initiative (SBTi). HitGen has pledged to set near-term science-based targets within the...HitGen Receives New Funding to Discover Novel Therapeutics for Underserved Diseases
Company enters into new agreement with the Gates Foundation to identify novel drug leads targeting tuberculosis and malaria and new agents for non-hormonal contraception. CHENGDU, China, Nov. 20, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), today announced that it has entered into a new contract agreement with the Gates Foundation. HitGen will leverage its industry-leading DNA-encoded library (DEL) platform to identify novel drug leads for tHitGen Receives New Funding to Discover Novel Therapeutics for Underserved Diseases
Company enters into new agreement with the Gates Foundation to identify novel drug leads targeting tuberculosis and malaria and new agents for non-hormonal contraception. CHENGDU, China, Nov. 20, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE:...HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor
BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technology platform, highlighting the value of DEL to accelerate innovative drug development. The initiation of the BGE-102 Phase 1 clinical study triggers a milestone payment to HitGen. CHENGDU, China, Sept. 15, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding HitGen
Sign Up For FreeTo access detailed company insights
HitGen Inc. is a rapidly developing biotech company headquartered in Chengdu, China, specializing in drug discovery and development of novel medicines and agrochemicals. The company utilizes advanced technology platforms, including DNA-encoded library technology and fragment-based drug discovery, to optimize small molecules and nucleic acid-based d... Read More
